Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms

Ann Hematol. 2015 Sep;94(9):1585-7. doi: 10.1007/s00277-015-2397-9. Epub 2015 May 16.

Authors

N Polverelli¹, L Catani, N Vianelli, M Baccarani, M Cavo, F Palandri

Affiliation

¹ Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "L. and A. Seràgnoli", St Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.

PMID: 25975976
DOI: 10.1007/s00277-015-2397-9

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antisickling Agents / administration & dosage*
Humans
Hydroxyurea / administration & dosage*
Male
Middle Aged
Nitriles
Platelet Count
Pyrazoles* / administration & dosage
Pyrazoles* / adverse effects
Pyrimidines
Pyrrolidines*
Splenomegaly* / blood
Splenomegaly* / chemically induced
Splenomegaly* / drug therapy
Sulfonamides*
Thrombocytosis* / blood
Thrombocytosis* / chemically induced
Thrombocytosis* / drug therapy

Substances

Antisickling Agents
Nitriles
Pyrazoles
Pyrimidines
Pyrrolidines
Sulfonamides
fedratinib
ruxolitinib
Hydroxyurea